Chan, Henry Lik YuenButí, MaríaLim, Young-SukAgarwal, KoshMarcellin, PatrickBrunetto, MauriziaChuang, Wan-LongÇelen, Mustafa Kemal2024-04-242024-04-242024Chan, H. L. Y., Butí, M., Lim, Y. S., Agarwal, K., Marcellin, P., Brunetto, M. ve diğerleri. (2024). Long-term treatment with tenofovir alafenamide for chronic hepatitis B results in high rates of viral suppression and favorable renal and bone safety. . American Journal of Gastroenterology, 119(3), 486-496.0002-9270https://doi.org/10.14309/ajg.0000000000002468https://hdl.handle.net/11468/23613INTRODUCTION: The results from 2 phase 3 studies, through 2 years, in chronic hepatitis B infection showed tenofovir alafenamide (TAF) had similar efficacy to tenofovir disoproxil fumarate (TDF) with superior renal and bone safety. We report updated results through 5 years. METHODS: Patients with HBeAg-negative or HBeAg-positive chronic hepatitis B infection with or without compensated cirrhosis were randomized (2:1) to TAF 25 mg or TDF 300 mg once daily in double-blind (DB) fashion for up to 3 years, followed by open-label (OL) TAF up to 8 years. Efficacy (antiviral, biochemical, and serologic), resistance (deep sequencing of polymerase/reverse transcriptase and phenotyping), and safety, including renal and bone parameters, were evaluated by pooled analyses. RESULTS: Of 1,298 randomized and treated patients, 866 receiving TAF (DB and OL) and 432 receiving TDF with rollover to OL TAF at year 2 (n = 180; TDF?TAF3y) or year 3 (n = 202; TDF?TAF2y) were included. Fifty (4%) TDF patients who discontinued during DB were excluded. At year 5, 85%, 83%, and 90% achieved HBV DNA <29 IU/mL (missing 5 failure) in the TAF, TDF?TAF3y, and TDF?TAF2y groups, respectively; no patient developed TAF or TDF resistance. Median estimated glomerular filtration rate (by using Cockcroft-Gault) declined <2.5 mL/min, and mean declines of <1% in hip and spine bone mineral density were seen at year 5 in the TAF group; patients in the TDF?TAF groups had improvements in these parameters at year 5 after switching to OL TAF. DISCUSSION: Long-term TAF treatment resulted in high rates of viral suppression, no resistance, and favorable renal and bone safety.eninfo:eu-repo/semantics/openAccessBone mineral densityChronic hepatitis B virus infectionTenofovir alafenamideTenofovir disoproxil fumarateViremia reductionArticle11934864962-s2.0-851805124853756105810.14309/ajg.0000000000002468Q1